Supportive effect of carnitine on hepatitis C virus eradication therapy

Supportive effect of carnitine on hepatitis C virus eradication therapy - Supportive effect of carnitine on HCV eradication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026079

Enrollment

Registered

2017-02-10

Start date

2015-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis type C, cirrhosis type C

Interventions

carnitine control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients over 20 years old 2)Chronic hepatitis type C or cirrhosis type C 3)HCV-RNA positive and HCV genotype 2 4)Patients obtained written informed consent 5)Carnitine <=91mmol/L

Exclusion criteria

Exclusion criteria: 1)Patients with oral intake difficulty 2)Patients with severe digestive disease 3)Pregnant woman, lactating woman, or a woman suspected of pregnancy 4)Patients with severe allergic reaction 5)Patients with drug abuse or psycological disorders 6)Carnitine >=92mmol/L

Design outcomes

Primary

Measure	Time frame
The degree of anemia progression at the end of anti-viral treatment	—

Secondary

Measure	Time frame
Sustained viral response (SVR) at 24 weeks	—

Countries

Japan

Contacts

Public ContactKEI MORIYA

Nara Medical University Third department of Internal Medicine

moriyak@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026